Niosome Encapsulated Adriamycin and Its Antitumor Activity
Author Information
Author(s): D.J. Kerr, A. Rogerson, G.J. Morrison, A.T. Florence, S.B. Kaye
Primary Institution: University of Glasgow and University of Strathclyde
Hypothesis
The encapsulation of adriamycin in niosomes will enhance its antitumor activity and alter its pharmacokinetics.
Conclusion
Niosome encapsulated adriamycin maintains its cytotoxic activity while reducing cardiac toxicity compared to free adriamycin.
Supporting Evidence
- Niosomal adriamycin showed similar clonogenic survival curves to free adriamycin in vitro.
- Growth delay for niosomal adriamycin was significantly longer than control.
- Niosomes altered the pharmacokinetics of adriamycin, leading to lower peak cardiac levels.
Takeaway
This study shows that wrapping a cancer drug in tiny bubbles called niosomes can help it work better against tumors and be less harmful to the heart.
Methodology
Niosomes were prepared and characterized, followed by in vitro and in vivo studies on human lung tumor cells and tumor-bearing nude mice.
Limitations
The study does not assess the long-term effects of niosome encapsulated adriamycin on cardiac health.
Participant Demographics
Nude mice with human lung tumor xenografts were used in the study.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% confidence limits
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website